This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Inhaled fluticasone is an effective maintenance therapy for asthmatic children but in recent years there have been several disturbing case reports of morbidity due to adrenal suppression among children treated with >400 μg/day, the maximum dose licensed by the FDA in the US for children with asthma.1–3 Investigators from Royal Hospital for Sick Children, Glasgow, UK studied asthmatic children receiving high-dose inhaled fluticasone to determine the prevalence of adrenal suppression. Records of all children treated in the respiratory clinics at the Royal Hospital for Sick Children were reviewed to identify patients who were prescribed inhaled fluticasone >400 μg/day from January 2000 to April 2002. Because of …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.